Multidrug-resistant tuberculosis (MDR-TB)

A course of treatment for uncomplicated tuberculosis (TB) takes a minimum of six months. When patients are resistant to the two most powerful first-line antibiotics (isoniazid and rifampicin), they are considered to have multidrug-resistant TB (MDR-TB).

MDR-TB is not impossible to treat, but the drug regimen is arduous, taking up to two years and causing many side effects.

Extensively drug-resistant tuberculosis (XDR-TB) is identified when patients show resistance to the second-line drugs administered for MDR-TB. The treatment options for XDR-TB are very limited. Two new drugs – bedaquiline and delamanid – have recently become available to some patients who have no other treatment options left.

In 2015 MSF treated 18,100 patients for TB, of whom 2,000 for MDR-TB.

For more information, please see tuberculosis.

Georgia
Tuberculosis (TB) is a major challenge in Georgia, with many people suffering from multi-drug...
Updates
“The intensification and proximity of fighting is clearly limiting access to the hospital,” said...
Op-ed
"The recommendations within the new WHO TB guidelines represent an opportunity for countries to...
Press release
MSF urges Indian Prime Minister not to cave to pressure from EU to accept trade deal that could...
Press release
“TB is curable, yet it is now the infectious disease that kills the most people in the world,” said...
Press release
"The price for delamanid needs to come down to an affordable level, and Otsuka should also register...
Press release
MSF appreciates Otsuka Pharmaceuticals’ donation of 400 treatments of a novel drug, delamanid,...
Report
Download the complete report (pdf) Geneva/Cape Town – Médecins Sans Frontières (MSF) and the...
Press release
“African leaders really should see this summit as an opportunity to work together with Prime...
Article
MSF strongly refutes the false allegations made in the media by the Humanitarian Committee of DPR...
Article
PNG's Gulf Province is largely a land without Land Cruisers, the four-wheeled workhorses used by...
Interview
Interview with Tetyana Pylypenko, Médecins Sans Frontières (MSF) Medical Team Leader. "The project...
Patient story
"When I was put on this new drug regimen I gained hope that I could be cured. I became cheerful and...
Updates
MSF says a new combination of drugs created to treat extensively drug-resistant TB (XDR-TB) is...
Crisis Update
MSF continues to expand its medical activities to meet the needs of people living in the hardest-...
Month in Focus
SYRIA – A humanitairan failure EBOLA - Remain vigilant ETHIOPIA – The plight of women refugees MDR-...

Pages